H. Tesch

发表

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer - clinical results and biomarker analysis of GeparNuevo study.

K. Weber, M. Rezai, P. Fasching, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease

B. Krug, V. Diehl, J. Franklin, 2001, Annals of Hematology.